Company profile: Oruka Therapeutics
1.1 - Company Overview
Company description
- Provider of biologic therapies for chronic skin diseases, including monoclonal antibodies: ORKA-001 targeting IL-23p19 for psoriasis and other inflammatory diseases; ORKA-002 targeting IL-17A/F for psoriasis and other inflammatory diseases; and ORKA-003, a discovery-stage program for psoriasis, psoriatic arthritis, and related conditions.
Products and services
- ORKA-002: A dual-target monoclonal antibody targeting interleukin-17A and interleukin-17F for the treatment of psoriasis and other inflammatory diseases
- ORKA-001: A subunit-specific monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23p19) for the treatment of psoriasis and other inflammatory diseases
- ORKA-003: A discovery-phase pipeline program aimed at treating psoriasis, psoriatic arthritis, and other related conditions, advancing innovative biologics for chronic skin diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oruka Therapeutics
Paradigm Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paradigm Therapeutics company profile →
Evaluate
HQ: United Kingdom
Website
- Description: Provider of trusted commercial intelligence for the pharmaceutical and medical device industries, offering EvaluatePharma online subscription services that deliver a standardized view of the global pharmaceutical market's past, present, and future. Offerings include data feeds integrating forecast, trial, and key event data, asset screening, competitive landscape analysis, commercial opportunity assessment, company profiling, and data-driven thought leadership.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evaluate company profile →
Navitas Life Sciences
HQ: United States
Website
- Description: Provider of services for Finbrin Split products and data science and supply chain solutions for large pharma, leveraging expert teams from TAKE Life Sciences and WCI Consulting and specialists in clinical development, regulatory, technology, and consulting to deliver client insights.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Navitas Life Sciences company profile →
Boca Biolistics
HQ: United States
Website
- Description: Provider of hybrid CRO and biobank services, delivering human biospecimens across oncology and other diseases; end-to-end contract research to support development and market approval of diagnostic technologies; CLIA-certified, CAP-accredited reference lab testing; COVID-19 serology and PCR; and oncology research solutions combining clinical research, data analytics, and industry leading clinical and molecular datasets to enable precision medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Boca Biolistics company profile →
Biose
HQ: France
Website
- Description: Provider of pharmaceuticals based on live bacteria, with 60 years of experience and specialized skills across discovery, process development, manufacturing, and registration, focused on health through microbiota and microbiome science.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biose company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oruka Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oruka Therapeutics
2.2 - Growth funds investing in similar companies to Oruka Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oruka Therapeutics
4.2 - Public trading comparable groups for Oruka Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →